iShares Neuroscience and Healthcare ETFNYSE Arca:IBRN
- LAST PRICE25.89
- TODAY'S CHANGE (%)0.00 (0.00%)
- Bid / Lots10.36/ 2
- Ask / Lots41.42/ 2
- Open / Previous Close--- / 25.89
- Day Range---
- 52 Week Range
- Volume---
- Overall Morningstar RatingNot Ratedout of 268 funds
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IBRN |
|---|---|---|
| 10:11 ET | 100 | 26.28 |
| 04:00 ET | 100 | 25.89 |
Daily Premium/Discount
| Date | Daily Premium/Discount |
|---|---|
| 08/20/2024 | -0.16% |
| 08/21/2024 | -0.16% |
| 08/22/2024 | -0.05% |
| 08/23/2024 | -0.10% |
| 08/26/2024 | -0.13% |
| 08/27/2024 | -0.05% |
| 08/28/2024 | -0.08% |
| 08/29/2024 | -0.10% |
| 08/30/2024 | -0.26% |
| 09/03/2024 | -0.31% |
| 09/04/2024 | -0.25% |
| 09/05/2024 | -0.32% |
| 09/06/2024 | -0.30% |
| 09/10/2024 | -0.19% |
| 09/11/2024 | -0.22% |
| 09/12/2024 | -0.30% |
| 09/13/2024 | -0.25% |
| 09/16/2024 | -0.23% |
| 09/17/2024 | -0.30% |
| 09/18/2024 | -0.09% |
| 09/19/2024 | -0.30% |
| 09/20/2024 | -0.13% |
| 09/23/2024 | -0.22% |
| 09/24/2024 | -0.12% |
| 09/25/2024 | -0.20% |
| 09/26/2024 | -0.12% |
| 09/27/2024 | -0.24% |
| 09/30/2024 | -0.21% |
| 10/01/2024 Largest Discount | -0.33% |
| 10/02/2024 | -0.23% |
| 10/03/2024 | -0.21% |
| 10/04/2024 | -0.25% |
| 10/07/2024 Largest Discount | -0.33% |
| 10/08/2024 | -0.17% |
| 10/09/2024 | -0.16% |
| 10/10/2024 | -0.28% |
| 10/11/2024 | -0.18% |
| 10/14/2024 | -0.18% |
| 10/15/2024 | -0.24% |
| 10/16/2024 | -0.20% |
| 10/17/2024 | -0.18% |
| 10/18/2024 | -0.24% |
| 10/21/2024 | -0.09% |
| 10/22/2024 | 0.00% |
| 10/23/2024 | -0.04% |
| 10/24/2024 | 0.01% |
| 10/25/2024 | 0.04% |
| 10/28/2024 | 0.02% |
| 10/29/2024 | -0.15% |
| 10/30/2024 | 0.01% |
| 10/31/2024 | 0.09% |
| 11/01/2024 | -0.13% |
| 11/04/2024 | 0.02% |
| 11/05/2024 | -0.12% |
| 11/06/2024 | -0.22% |
| 11/08/2024 | -0.16% |
| 11/11/2024 | 0.00% |
| 11/12/2024 | 2.66% |
| 11/13/2024 | 4.03% |
| 11/14/2024 Largest Premium | 6.03% |
| 11/15/2024 | -0.17% |
| US Stock | 82.5% |
|---|---|
| Non-US Stock | 17.3% |
| Cash | 0.3% |
| Convertible | 0 |
| Non-US Bond | 0 |
| Other | 0 |
| Healthcare | 99.7% |
|---|---|
| Basic Mat. | 0 |
| Communication Services | 0 |
| Consumer Cyclical | 0 |
| Consumer Defensive | 0 |
| Energy | 0 |
| Financial Serv.s | 0 |
| Industrials | 0 |
| Real Estate | 0 |
| Technology | 0 |
| Utilities | 0 |
| United States | 82.7% |
|---|---|
| Asia/Oceania | 6.4% |
| Canada | 3.9% |
| Europe | 1.9% |
| Africa | 0 |
| Latin America | 0 |
| Company Name sortable | Position sortable | Allocation sortable | Allocation sortable1 Month Change | Market Value sortable |
|---|---|---|---|---|
Biohaven Ltd | Long | 4.9% | 0.00% | $195.2K |
PTC Therapeutics Inc | Long | 4.6% | 0.00% | $183.2K |
Intra-Cellular Therapies Inc | Long | 4.2% | 0.00% | $166.9K |
Catalyst Pharmaceuticals Inc | Long | 4.0% | 0.00% | $159.2K |
SK Biopharmaceuticals Co Ltd Ordinary Shares | Long | 3.9% | 0.00% | $157.7K |
argenx SE ADR | Long | 3.9% | 0.00% | $156.5K |
Xenon Pharmaceuticals Inc | Long | 3.9% | 0.00% | $154.7K |
Axonics Inc | Long | 3.7% | 0.00% | $147.9K |
Neurocrine Biosciences Inc | Long | 3.6% | 0.00% | $144.9K |
Longboard Pharmaceuticals Inc | Long | 3.6% | 0.00% | $142.6K |
Reports
Morningstar Ratings
| Time Horizon | Star Rating |
|---|---|
| Overall Rating | Not Rated |
| 3 Year Rating | Not Rated |
| 5 Year Rating | Not Rated |
| 10 Year Rating | Not Rated |
Past performance is no guarantee of future results. The ratings reflect historical risk-adjusted performance, and the overall rating is derived from a weight average of the fund's 3, 5, and 10 year (Morningstar Rating) metrics.
Style Box is calculated only using the long position holdings of the portfolio.
Best Fit Index | NYSE FactSet Glb NeuBio&MedTech TR USD |
|---|---|
Category | |
Sponsor | BlackRock Fund Advisors |
Inception | August 24, 2022 |
The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience. The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index. It is non-diversified.
| Total Net Assets | $4.0M |
|---|---|
| Shares Out. | 150.0K |
| Net Asset Value (NAV) | $25.93 |
| Prem/Discount to NAV | -0.17% |
| P/E Ratio | --- |
| Dividend Yield | 0.06% |
| Dividend per Share | --- |
| Ex-Dividend Date | --- |
| Dividend Payment Date | --- |
| Beta | --- |
| Morningstar Investment Style | Health |
| Equity Style | Small Cap Growth |
| Credit Quality / Duration | --- |
| Actual Management Fee | 0.47% |
|---|---|
| Actual Mgmt. Expense Ratio (MER) | 0.47% |